Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients
Open Access
- 7 November 2005
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 35 (11) , 3376-3386
- https://doi.org/10.1002/eji.200526248
Abstract
Impairment of purine metabolism due to adenosine deaminase (ADA) deficiency is associated with a severe combined immunodeficiency (SCID). Polyethylene glycol-modified ADA (PEG-ADA) has provided noncurative, life-saving treatment for these patients, but full immune recovery is not achieved with this therapy. Since ADA-SCID is perhaps the most difficult form of SCID to handle clinically, understanding the benefits and limitations of PEG-ADA therapy may be relevant for treatment selection. To this purpose, we analyzed the rate of thymic output, T and B cell repertoires, number of T cell divisions, IFN-γ and IL-4 production, and the extent of cell death in five ADA-SCID patients following a prolonged period of treatment with PEG-ADA. We found that thymic output was low in these patients. However, their T cell repertoire was heterogeneous, and their T lymphocytes produced cytokines upon activation and responded to mitogen stimulation, although with different kinetics. Furthermore, a high number of peripheral T lymphocytes were committed to apoptosis. Anomalies were also observed in the B cell compartment, with oligoclonal expansions of B cell clonotypes in two patients. Our data indicate that decreased thymic function, B cell oligoclonality, and increased spontaneous apoptosis may be the mechanisms by which the immunodeficiency of ADA-SCID patients persists in spite of treatment with PEG-ADA.Keywords
This publication has 40 references indexed in Scilit:
- Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasiaBlood, 2002
- Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trialBlood, 2002
- Immunophenotyping of blood lymphocytes in childhoodReference values for lymphocyte subpopulationsThe Journal of Pediatrics, 1997
- Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infantsThe Journal of Pediatrics, 1997
- Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome cPublished by Elsevier ,1996
- T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 YearsScience, 1995
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995
- T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.Journal of Clinical Investigation, 1993
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987
- ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITYThe Lancet, 1972